Nichi Iko Pharmaceutical Co (4541 JP)

Q2 Financial Results Briefing for the Fiscal Year Ending March 2021

Speakers

• Yuichi Tamura (President and CEO, Nichi-Iko Pharmaceutical Co., Ltd.)
• Takahiro Yoshikawa (Representative Director and Executive Vice President, Nichi-Iko Pharmaceutical Co., Ltd.)
• Kenji Akane (Director and Executive Vice President, Nichi-Iko Pharmaceutical Co., Ltd.)
• Noboru Inasaka (Executive Managing Director, Nichi-Iko Pharmaceutical Co., Ltd.)
• Shuji Ishida (Operating Officer, Head of Administrative Division, Nichi-Iko Pharmaceutical Co., Ltd.)
• Hiroshi Shimazaki (Operating Officer, Head of Quality Assurance & Pharmacovigilance Division, Nichi-Iko Pharmaceutical Co., Ltd.)
• Takashi Kashiwagi (Operating Officer, Head of Corporate Planning Division, Nichi-Iko Pharmaceutical Co., Ltd.)
• Susumu Kanda (Operating Officer, Manager of President's Office, Nichi-Iko Pharmaceutical Co., Ltd.)

Analysts

• Hidemaru Yamaguchi (Analyst, Citigroup Global Markets Japan Inc.)
• Fumiyoshi Sakai (Analyst, Credit Suisse Securities (Japan) Limited)
• Masao Yoshida (Senior Analyst, Ichiyoshi Research Institute Inc.)
• Shinichiro Muraoka (Analyst, Morgan Stanley MUFG Securities Co., Ltd.)
• Takashi Akahane (Analyst, Tokai Tokyo Research Institute Co., Ltd.)